Cargando…
Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
5-FU cytotoxicity mechanism has been assigned both to the miss-incorporation of fluoronucleotides into RNA and DNA and to the inhibition of thymidylate synthase. 5-FU is one of the most widely used chemotherapeutic drugs, although it has severe side effects that may vary between patients. Pharmacoge...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917556/ https://www.ncbi.nlm.nih.gov/pubmed/27445811 http://dx.doi.org/10.3389/fphar.2016.00172 |
_version_ | 1782438958040350720 |
---|---|
author | Negrei, Carolina Hudita, Ariana Ginghina, Octav Galateanu, Bianca Voicu, Sorina Nicoleta Stan, Miriana Costache, Marieta Fenga, Concettina Drakoulis, Nikolaos Tsatsakis, Aristidis M. |
author_facet | Negrei, Carolina Hudita, Ariana Ginghina, Octav Galateanu, Bianca Voicu, Sorina Nicoleta Stan, Miriana Costache, Marieta Fenga, Concettina Drakoulis, Nikolaos Tsatsakis, Aristidis M. |
author_sort | Negrei, Carolina |
collection | PubMed |
description | 5-FU cytotoxicity mechanism has been assigned both to the miss-incorporation of fluoronucleotides into RNA and DNA and to the inhibition of thymidylate synthase. 5-FU is one of the most widely used chemotherapeutic drugs, although it has severe side effects that may vary between patients. Pharmacogenetic studies related to 5-FU have been traditionally focused on the rate-limiting catabolic enzyme, dihydropyrimidine dehydrogenase that breaks 80–85% of 5-FU into its inactive metabolite. Choosing the right dosing scheme and chemotherapy strategy for each individual patient remains challenging for personalized chemotherapy management. In the general effort toward reduction of colorectal cancer mortality, in vitro screening studies play a very important role. To accelerate translation research, increasing interest has been focused on using in vivo-like models such as three-dimensional spheroids. The development of higher throughput assays to quantify phenotypic changes in spheroids is an active research area. Consequently, in this study we used the microarray technology to reveal the HT-29 colorectal adenocarcinoma cells gene expression signature as response to 5-FU/OXP/FA treatment in a state of the art 3D culture system. We report here an increased reactive oxygen species production under treatment, correlated with a decrease in cell viability and proliferation potential. With respect to the HT-29 cells gene expression under the treatment with 5-FU/OXP/FA, we found 15.247 genes that were significantly differentially expressed (p < 0.05) with a fold change higher that two-fold. Among these, 7136 genes were upregulated and 8111 genes were downregulated under experimental conditions as compared to untreated cells. The most relevant and statistic significant (p < 0.01) pathways in the experiment are associated with the genes that displayed significant differential expression and are related to intracellular signaling, oxidative stress, apoptosis, and cancer. |
format | Online Article Text |
id | pubmed-4917556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-49175562016-07-21 Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment Negrei, Carolina Hudita, Ariana Ginghina, Octav Galateanu, Bianca Voicu, Sorina Nicoleta Stan, Miriana Costache, Marieta Fenga, Concettina Drakoulis, Nikolaos Tsatsakis, Aristidis M. Front Pharmacol Pharmacology 5-FU cytotoxicity mechanism has been assigned both to the miss-incorporation of fluoronucleotides into RNA and DNA and to the inhibition of thymidylate synthase. 5-FU is one of the most widely used chemotherapeutic drugs, although it has severe side effects that may vary between patients. Pharmacogenetic studies related to 5-FU have been traditionally focused on the rate-limiting catabolic enzyme, dihydropyrimidine dehydrogenase that breaks 80–85% of 5-FU into its inactive metabolite. Choosing the right dosing scheme and chemotherapy strategy for each individual patient remains challenging for personalized chemotherapy management. In the general effort toward reduction of colorectal cancer mortality, in vitro screening studies play a very important role. To accelerate translation research, increasing interest has been focused on using in vivo-like models such as three-dimensional spheroids. The development of higher throughput assays to quantify phenotypic changes in spheroids is an active research area. Consequently, in this study we used the microarray technology to reveal the HT-29 colorectal adenocarcinoma cells gene expression signature as response to 5-FU/OXP/FA treatment in a state of the art 3D culture system. We report here an increased reactive oxygen species production under treatment, correlated with a decrease in cell viability and proliferation potential. With respect to the HT-29 cells gene expression under the treatment with 5-FU/OXP/FA, we found 15.247 genes that were significantly differentially expressed (p < 0.05) with a fold change higher that two-fold. Among these, 7136 genes were upregulated and 8111 genes were downregulated under experimental conditions as compared to untreated cells. The most relevant and statistic significant (p < 0.01) pathways in the experiment are associated with the genes that displayed significant differential expression and are related to intracellular signaling, oxidative stress, apoptosis, and cancer. Frontiers Media S.A. 2016-06-23 /pmc/articles/PMC4917556/ /pubmed/27445811 http://dx.doi.org/10.3389/fphar.2016.00172 Text en Copyright © 2016 Negrei, Hudita, Ginghina, Galateanu, Voicu, Stan, Costache, Fenga, Drakoulis and Tsatsakis. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Negrei, Carolina Hudita, Ariana Ginghina, Octav Galateanu, Bianca Voicu, Sorina Nicoleta Stan, Miriana Costache, Marieta Fenga, Concettina Drakoulis, Nikolaos Tsatsakis, Aristidis M. Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment |
title | Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment |
title_full | Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment |
title_fullStr | Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment |
title_full_unstemmed | Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment |
title_short | Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment |
title_sort | colon cancer cells gene expression signature as response to 5- fluorouracil, oxaliplatin, and folinic acid treatment |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917556/ https://www.ncbi.nlm.nih.gov/pubmed/27445811 http://dx.doi.org/10.3389/fphar.2016.00172 |
work_keys_str_mv | AT negreicarolina coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment AT huditaariana coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment AT ginghinaoctav coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment AT galateanubianca coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment AT voicusorinanicoleta coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment AT stanmiriana coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment AT costachemarieta coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment AT fengaconcettina coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment AT drakoulisnikolaos coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment AT tsatsakisaristidism coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment |